Skip to main content
. Author manuscript; available in PMC: 2020 Oct 1.
Published in final edited form as: J Thorac Oncol. 2019 Jun 11;14(10):1847–1852. doi: 10.1016/j.jtho.2019.05.041

Figure 1. Waterfall plot of response to AZD4547.

Figure 1.

Each vertical bar represents a patient’s best percent decrease in tumor burden when compared to baseline as defined by RECIST 1.1. Only patients with measurable disease at baseline are presented in the plot. Patients who did not have follow up tumor disease assessment were presented at the very left of the plot marked with ‘NA’. Patients who had new lesions appear at their first follow-up assessment or who expired prior to the first scheduled the disease assessment and the death can reasonably be assumed to be due to disease progression are represented graphically as a 100% increase in tumor burden. Patients who had symptomatic deterioration at first disease assessment are coded as “Symptomatic deterioration”. Patients who expired prior to disease assessment, but the death was not due to disease were coded as ‘Early death’. Negative numbers represent decrease in tumor burden from baseline while positive numbers represent increase in tumor burden from baseline.